GlassScriptPhysician profile
Richard Schroer
NPI 1669463220
$393.03
in general payments reported to CMS, 2019-2025
10 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.90 · 2021: $30.83 · 2023: $47.11 · 2024: $42.83 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.30 |
| Education | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intrabio INC | $149.69 | 2025 | Aqneursa |
| Mirum Pharmaceuticals, INC. | $48.13 | 2023-2025 | Cholbam, Cholbam |
| Biomarin Pharmaceutical INC. | $41.57 | 2023-2024 | Palynziq |
| Ptc Therapeutics, INC. | $38.41 | 2025 | Sephience |
| Ultragenyx Pharmaceutical INC. | $30.00 | 2021 | |
| Medunik USA INC. | $25.09 | 2025 | Pheburane |
| Zevra Therapeutics INC | $23.17 | 2024 | Olpruva |
| Cycle Pharmaceuticals INC | $19.24 | 2025 | Javygtor, Nityr |
| Genzyme Corporation | $14.41 | 2019 | |
| Travere Therapeutics, INC. | $3.32 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Schroer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.